Literature DB >> 8723466

Penetration and bactericidal activity of cefixime in synovial fluid.

E Somekh1, L Heifetz, M Dan, F Poch, H Hafeli, A Tanai.   

Abstract

The penetration of oral cefixime into the synovial fluids of 16 patients (mean age, 50.6 years) who underwent joint taps for rheumatic noninfectious disorders was examined. The patients were each given a single dose (400 mg) 2 to 24 h prior to the tap. Cefixime concentrations in serum and joint fluid samples were measured by high-performance liquid chromatography, and the bactericidal activities of these fluids against three isolates each of Haemophilus influenzae and Escherichia coli were examined. The highest concentrations in serum and synovial fluid were achieved 4 h following drug intake, the mean values being 2.8 and 2.03 micrograms/ml, respectively. Effective bactericidal activities (bactericidal titer, > 1:2) against E. coli and H. influenzae were demonstrated in serum and joint fluid up to 10 h following oral intake of cefixime. These results suggest that cefixime penetrates well into joint fluid, achieving levels above the MIC for E. coli lasting as long as 10 h and levels above the MIC for H. influenzae lasting up to 24 h after administration. Good bactericidal activity against susceptible bacterial isolates was observed for at least 10 h after dosing.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8723466      PMCID: PMC163291          DOI: 10.1128/AAC.40.5.1198

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  3 in total

1.  The pharmacokinetic and bactericidal characteristics of oral cefixime.

Authors:  D C Brittain; B E Scully; T Hirose; H C Neu
Journal:  Clin Pharmacol Ther       Date:  1985-11       Impact factor: 6.875

2.  Pharmacokinetics of cefixime after once-a-day and twice-a-day dosing to steady state.

Authors:  R D Faulkner; W Bohaychuk; R E Desjardins; Z M Look; J D Haynes; A I Weiss; B M Silber
Journal:  J Clin Pharmacol       Date:  1987-10       Impact factor: 3.126

3.  Absolute bioavailability of cefixime in man.

Authors:  R D Faulkner; P Fernandez; G Lawrence; L L Sia; A J Falkowski; A I Weiss; A Yacobi; B M Silber
Journal:  J Clin Pharmacol       Date:  1988-08       Impact factor: 3.126

  3 in total
  2 in total

1.  Staphylococcal persistence due to biofilm formation in synovial fluid containing prophylactic cefazolin.

Authors:  Sana S Dastgheyb; Sommer Hammoud; Constantinos Ketonis; Andrew Yongkun Liu; Keith Fitzgerald; Javad Parvizi; James Purtill; Michael Ciccotti; Irving M Shapiro; Michael Otto; Noreen J Hickok
Journal:  Antimicrob Agents Chemother       Date:  2015-01-26       Impact factor: 5.191

2.  [Adult onset septic coxitis : etiology, diagnostics, indication for and technique of open revision of the hip].

Authors:  R Gaulke; C Krettek
Journal:  Unfallchirurg       Date:  2012-11       Impact factor: 1.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.